NASDAQ: LSTALisata Therapeutics Inc Stock
$2.83+0.18 (+6.79%)
Updated Apr 24, 2024
LSTA Price
$2.83
Fair Value Price
$2.76
Market Cap
$23.51M
52 Week Low
$1.95
52 Week High
$4.53
P/E
-1.1x
P/B
0.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$20M
Beta
0.57
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LSTA Overview
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LSTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LSTA ($2.83) is overvalued by 2.51% relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LSTA ($2.83) is not significantly undervalued (2.51%) relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LSTA due diligence checks available for Premium users.
Be the first to know about important LSTA news, forecast changes, insider trades & much more!
LSTA News
Valuation
LSTA fair value
Fair Value of LSTA stock based on Discounted Cash Flow (DCF)
Price
$2.83
Fair Value
$2.76
Overvalued by
2.51%
LSTA ($2.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LSTA ($2.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LSTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.1x
Industry
15.69x
Market
41.27x
LSTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
5.86x
LSTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LSTA's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
LSTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$54.7M
Liabilities
$6.8M
Debt to equity
0.14
LSTA's short-term assets ($53.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LSTA's short-term assets ($53.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LSTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LSTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
-$5.7M
Financing
$24.0k
LSTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LSTA vs Biotech Stocks
Lisata Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.